Syros Pharmaceuticals has been granted a patent for compounds that selectively inhibit CDK7, inducing cellular apoptosis and inhibiting transcription of disease-related genes. The compounds can be used in treating various diseases, including cancers, benign neoplasms, pathologic angiogenesis, and fibrotic diseases. GlobalData’s report on Syros Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Syros Pharmaceuticals Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Syros Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Syros Pharmaceuticals's grant share as of April 2024 was 25%. Grant share is based on the ratio of number of grants to total number of patents.

Cdk7 inhibitors for treating cancer and other diseases

Source: United States Patent and Trademark Office (USPTO). Credit: Syros Pharmaceuticals Inc

The granted patent (Publication Number: US11918592B2) discloses a compound of Formula I and its various derivatives, including pharmaceutically acceptable salts, stereoisomers, or isotopic forms. The compound is further specified by the presence of certain substituents at specific positions, such as -OH, -CN, -C(O)NH2, -chloro, or -CF3. Additionally, the patent claims cover a pharmaceutical composition containing the disclosed compound and a method for treating diseases associated with aberrant activity of CDK7 by administering the compound or its derivatives to patients. The diseases targeted include proliferative diseases, infectious diseases, and those caused by expanded repeats of simple nucleotide tracts, with specific examples like cancer, viral infections, Huntington's Disease, myotonic dystrophy, and amyotrophic lateral sclerosis (ALS) mentioned.

Moreover, the patent extends to methods involving the administration of a second agent along with the disclosed compound, where the second agent could be an anti-proliferative agent, an anti-cancer agent, an immunosuppressant, or a pain-relieving agent. The patent also encompasses a broader range of compounds beyond Formula I, with similar therapeutic applications for treating diseases associated with CDK7 activity. The diseases targeted include various types of cancers, benign neoplasms, pathologic angiogenesis, and fibrotic diseases, with specific examples provided for different cancer types like blood cancer, bone cancer, brain cancer, breast cancer, lung cancer, melanoma, neuroblastoma, and ovarian cancer. The patent's comprehensive coverage of compounds, pharmaceutical compositions, and treatment methods highlights its potential significance in the development of therapies for a wide range of diseases linked to CDK7 dysregulation.

To know more about GlobalData’s detailed insights on Syros Pharmaceuticals, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies